Higher levels of IL‐6 early after tocilizumab distinguish survivors from nonsurvivors in COVID‐19 pneumonia: A possible indication for deeper targeting of IL‐6

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy

(2020) Paola Toniati et al.   AUTOIMMUNITY REVIEWS

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

(2020) Emanuele Pontali et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care

(2020) Luca Quartuccio et al.   JOURNAL OF CLINICAL VIROLOGY

Tocilizumab treatment in COVID-19: A single center experience

(2020) Pan Luo et al.   JOURNAL OF MEDICAL VIROLOGY

Clinical Outcomes in COVID‐19 Patients Treated with Tocilizumab: An Individual Patient Data Systematic Review

(2020) Daniel Antwi‐Amoabeng et al.   JOURNAL OF MEDICAL VIROLOGY

COVID‐19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients

(2020) Chiranjib Chakraborty et al.   JOURNAL OF MEDICAL VIROLOGY

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

(2020) Matthew J Cummings et al.   LANCET

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs)

(2020) Damemarie Paul et al.   JOURNAL OF MEDICAL ECONOMICS

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

(2020) Dennis McGonagle et al.   AUTOIMMUNITY REVIEWS

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy

(2019) Lara L. Riegler et al.   Therapeutics and Clinical Risk Management

Comparison of the clinical characteristics and severity of community-acquired pneumonia between patients with rheumatoid arthritis treated with tocilizumab and those treated with TNF inhibitor

(2018) Yoshiki Nagai et al.   Modern Rheumatology

Proinflammatory Cytokines, Aging, and Age-Related Diseases

(2013) Martin Michaud et al.   Journal of the American Medical Directors Association

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD